Neoadjuvant PD-1 blockade in patients with resectable melanoma followed by adjuvant maintenance results in early immunological effects driving clinical benefit and reveals transcriptional and genomic mechanisms of response.
- Alexander C. Huang
- Robert J. Orlowski
- Tara C. Mitchell